Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.

被引：1

作者：

Krug, Utz ^{[1
]}

Knoblauch, Nicola ^{[1
]}

Gerss, Joachim ^{[1
]}

Schliemann, Christoph ^{[1
]}

Wiebe, Stefanie ^{[1
]}

Mueller-Tidow, Carsten ^{[1
]}

Berdel, Wolfgang E. ^{[1
]}

机构：

[1] Univ Hosp Muenster, Munster, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.7053

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7053

引用

页数：1

共 50 条

[31] Analysis of the Short-Term Efficacy of Decitabine Combined with Low-Dose Cytarabine in the Treatment of JMML
Cai, Yuli
Liang, Weiru
Yi, Meihui
Zhang, Xiaoyan
Liu, Fang
Chang, Lixian
Guo, Ye
Chen, Yumei
Zou, Yao
Yang, Wenyu
Zhu, Xiaofan
BLOOD, 2020, 136
[32] LOW-DOSE METHOTREXATE TREATMENT IN ELDERLY PATIENTS WITH BULLOUS PEMPHIGOID
PAUL, MA
JORIZZO, JL
FLEISCHER, AB
WHITE, WL
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 31 (04) : 620 - 625
[33] The combination of Bemcentinib, a novel, oral, selective Axl-inhibitor and low-dose cytarabine yields durable responses in Aml patients unfit for intensive chemotherapy
Loges, S.
Heuser, M.
Chromik, J.
Vigil, C. E.
Paschka, P.
Re, F.
Di Renzo, N.
Lemoli, R.
Mattei, D.
Ben-Batalla, I
Hellesoy, M.
Micklem, D.
Holt, R. J.
Smethurst, D.
Lorens, K.
Lorens, J. B.
Shoaib, M.
Aly, H.
Brown, A.
Fiedler, W. M.
Cortes, J. E.
Gjertsen, B. T.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 6 - 6
[34] Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Doehner, Hartmut
Luebbert, Michael
Fiedler, Walter
Fouillard, Loic
Haaland, Alf
Brandwein, Joseph M.
Lepretre, Stephane
Reman, Oumedaly
Turlure, Pascal
Ottmann, Oliver G.
Mueller-Tidow, Carsten
Kraemer, Alwin
Raffoux, Emmanuel
Doehner, Konstanze
Schlenk, Richard F.
Voss, Florian
Taube, Tillmann
Fritsch, Holger
Maertens, Johan
BLOOD, 2014, 124 (09) : 1426 - 1433
[35] Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine
Faderl, Stefan
Ravandi, Farhad
Garcia-Manero, Guillermo
Huang, Xuelin
Jabbour, Elias
Kadia, Tapan
Ferrajoli, Alessandra
Estrov, Zeev
Feliu, Jennie
Schroeder, Heather
Kwari, Monica
Kantarjian, Hagop
BLOOD, 2010, 116 (21) : 152 - 152
[36] Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility
Wang, Y.
Xu, L. P.
Liu, K. Y.
Liu, D. H.
Wang, J.
Chen, H.
Chen, Y. H.
Han, W.
Huang, X. J.
BONE MARROW TRANSPLANTATION, 2011, 46 (06) : 892 - 898
[37] Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility
Y Wang
L P Xu
K Y Liu
D H Liu
J Wang
H Chen
Y H Chen
W Han
X J Huang
Bone Marrow Transplantation, 2011, 46 : 892 - 898
[38] A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML
Wei, Andrew H.
Sadawarte, Sonali
Catalano, John
Hills, Robert
Avery, Sharon
Patil, Sushrut S.
Burnett, Alan
Spencer, Andrew
BLOOD, 2010, 116 (21) : 1351 - 1352
[39] Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival
Arthur, Christopher
Jeffrey, Anthony
Yip, Eva
Katsioulas, Vicki
Nalpantidis, Anastasios
Kerridge, Ian
Greenwood, Matthew
Coyle, Luke
Mackinlay, Naomi
Fay, Keith
Enjeti, Anoop
Shortt, Jake
Stevenson, William
LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 831 - 839
[40] Personalized and Optimized Low-Dose and Intensive Chemotherapy Treatments for Patients with Acute Myeloid Leukemia (AML)
Quiroga-Campano, Ana Luz
Enfield, Louise
Foster, Matthew
Kostoglou, Margaritis
Georgiadis, Michael
Mantalaris, Athanasios
Panoskaltsis, Nicki
BLOOD, 2018, 132

← 1 2 3 4 5 →